Compugen (CGEN) Stock Price, News & Analysis

Company Overview

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression. By integrating genomic, transcriptomic and proteomic data, the platform accelerates target identification and reduces the timelines typically associated with early-stage drug discovery. The company applies this technology both to its internally developed pipeline and to partnered research programs.

The company’s pipeline includes multiple clinical-stage immuno-oncology candidates, among them checkpoint modulators advancing in Phase 1 trials for solid tumors. In parallel, Compugen is developing companion diagnostic and biomarker assays designed to predict patient response and optimize therapeutic regimens. Strategic collaborations with global pharmaceutical partners have enabled the advancement of select programs into later-stage development and expanded the geographic reach of its assets.

Over its three-decade history, Compugen has built a multidisciplinary team of computational biologists, immunologists and clinical development experts. This leadership group oversees both discovery and translational research efforts, with the goal of delivering novel immunotherapy solutions across North America, Europe and Asia. Through its integrated approach, Compugen aims to bring first-in-class therapies and precision diagnostic tools to patients with unmet medical needs.

Key Stats

• Today's Range: $1.34 to $1.39
• 50-Day Range: $1.34 to $1.69
• 52-Week Range: $1.13 to $2.66
• Volume: 92,574 shs
• Average Volume: 380,612 shs
• Market Capitalization: $121.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Buy

Compugen Stock Analysis - MarketRank™

Compugen scored higher than 33% of companies evaluated by MarketBeat, and ranked 807th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Compugen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Compugen has a consensus price target of $4.00, representing about 195.2% upside from its current price of $1.36.

Amount of Analyst Coverage

Compugen has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Compugen are expected to decrease in the coming year, from ($0.03) to ($0.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Compugen is -6.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Compugen is -6.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Compugen has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

1.17% of the float of Compugen has been sold short.

Short Interest Ratio / Days to Cover

Compugen has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Compugen has recently increased by 4.25%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Compugen does not currently pay a dividend.

Dividend Growth

Compugen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.17% of the float of Compugen has been sold short.

Short Interest Ratio / Days to Cover

Compugen has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Compugen has recently increased by 4.25%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Compugen has a news sentiment score of 1.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Compugen this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for CGEN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

2 people have added Compugen to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Compugen insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.50% of the stock of Compugen is held by insiders.

Percentage Held by Institutions

Only 12.22% of the stock of Compugen is held by institutions.

CGEN Stock Analysis - Frequently Asked Questions

How have CGEN shares performed this year?

Compugen's stock was trading at $1.53 at the start of the year. Since then, CGEN stock has decreased by 11.4% and is now trading at $1.3550.

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) announced its quarterly earnings data on Wednesday, August, 6th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by $0.01. The biotechnology company had revenue of $1.26 million for the quarter, compared to analysts' expectations of $3.95 million. Compugen had a negative trailing twelve-month return on equity of 34.77% and a negative net margin of 87.45%.
Read the conference call transcript.

Who are Compugen's major shareholders?

Compugen's top institutional shareholders include ARK Investment Management LLC (1.20%), Taylor Frigon Capital Management LLC (1.11%), Jane Street Group LLC (0.44%) and Rothschild Investment LLC (0.20%).

How do I buy shares of Compugen?

Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Compugen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXDW), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), PayPal (PYPL) and

Company Calendar

• Last Earnings: 8/06/2025
• Today: 9/17/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CGEN
• CIK: 1119774
• Web: www.cgen.com
• Phone: (723) 765-8585
• Fax: 972-3765-8555
• Employees: 70
• Year Founded: 1993

Price Target and Rating

• Average Price Target for Compugen: $4.00
• High Price Target: $4.00
• Low Price Target: $4.00
• Potential Upside/Downside: +194.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.23 million
• Net Margins: -87.45%
• Pretax Margin: -67.03%
• Return on Equity: -34.77%
• Return on Assets: -16.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.74
• Quick Ratio: 4.74

Sales & Book Value

• Annual Sales: $27.86 million
• Price / Sales: 4.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.62 per share
• Price / Book: 2.19

Miscellaneous

• Outstanding Shares: 89,240,000
• Free Float: 80,759,000
• Market Cap: $121.37 million
• Optionable: Optionable
• Beta: 2.58